DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dexcom Inc. To summarize, we found that Dexcom Inc ranked in the 54th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Dexcom Inc ended up being:
The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 71.01% of US equities in the Healthcare sector yielding a positive free cash flow.
The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.84%; that's greater than 88.35% of US stocks we're applying DCF forecasting to.
The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 16.63% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
FONR, REGN, UNH, CMD, and FZMD can be thought of as valuation peers to DXCM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Increasing launch of wearable medical devices is expected to propel growth of Asia Pacific smart medical devices market over the forecast period. For instance, in January 2020, VivaLNK, a China-based provider of connected healthcare solutions for in-patient and remote patient
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is growing rapidly worldwide—sedentary lifestyles being a key reason for that. A recent report by the World Health Organization (WHO) revealed that deaths from diabetes surged 70% globally between 2019 and 2020. Abbott and Dexcom are some of the names that are developing diabetes monitoring systems. Using the TipRanks Stock Comparison tool, we will place Abbott and Dexcom alongside each other and pick the stock reflecting a more compelling play.
InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Continuous Glucose Monitoring (CGM) Sensors Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue & Volume Forecast Till 2028” According to the